UK practitioners cannot advertise Botox or any other botulinum toxin product to the public. Botulinum toxin is a prescription-only medicine, and Regulation 284 of the Human Medicines Regulations 2012 prohibits advertisements likely to lead to its public use. The MHRA Blue Guide and the CAP Code apply this across websites, social posts, and clinic price lists.
Why botulinum toxin sits inside the POM advertising ban
Botulinum toxin in all its UK-licensed brands (Botox, Azzalure, Bocouture, Alluzience, Letybo) is a prescription-only medicine. POMs have a particular legal status under the Human Medicines Regulations 2012, the statutory instrument that governs medicines law in the UK.
Regulation 284(1) is the central provision. It states: "A person may not publish an advertisement that is likely to lead to the use of a prescription only medicine." The narrow exception for approved vaccination campaigns does not apply to aesthetics. The prohibition is absolute, technology-neutral, and applies to anyone publishing the ad, whether the clinic, the staff member, the agency, or the influencer.
The MHRA's role is to enforce that frame. Its Blue Guide on advertising and promotion of medicines is the practical reference document the agency publishes, restating the legal position and giving worked examples. The Blue Guide is the document a practitioner is expected to know exists, and its existence is one of the reasons "I didn't realise" is not a defence in front of the regulator.
How the MHRA Blue Guide frames it
The Blue Guide is explicit that POMs may be promoted to healthcare professionals and others authorised to prescribe or supply them. They cannot be promoted to the public. The practical consequence for aesthetic clinics is that any patient-facing material, the clinic website, the Instagram grid, the printed price list, the consultation room poster, sits inside the consumer-advertising frame and inside the POM ban.
The Blue Guide also notes that a medicine's advertising is judged on substance and effect, not on whether the brand name is technically present. An "anti-wrinkle injection from £180" page, with imagery and language that any reasonable consumer reads as referring to botulinum toxin, is captured. The MHRA position has been steady on this for over a decade, and the GOV.UK guidance on advertising your medicines restates the principle for non-specialists.
What the CAP Code and ASA add
The Committee of Advertising Practice writes the rules the Advertising Standards Authority enforces against marketing communications. CAP Code rule 12.12 states that prescription-only medicines or treatments may not be advertised to the public. The ASA's public-facing advice on Botox advertising lists what marketers cannot do: name the brand, name the active substance, use before-and-after photographs, use celebrity or influencer endorsements, or run any of the indirect references the rule is designed to capture. Hashtags including the brand name fall on the wrong side of the line.
The ASA's enforcement notice on Botox and botulinum toxin injections is the document the field treats as the template. It cites Regulation 284 and the Blue Guide directly. It tells clinics that any reference to a POM in a public-facing ad, including indirect references, falls on the wrong side. The ASA has acted on this consistently, with a steady stream of upheld rulings against UK clinics through 2023 and 2024 for naming the brand or active substance in public-facing ads.
What a UK practitioner can put on a website
The ASA's practical guidance for clinics sets out what is workable. The shape of a compliant clinic website looks like this:
- Homepage focuses on the service, not the medicine. The page can describe consultations for lines and wrinkles. It cannot name the POM.
- No POM references in price lists, navigation, or hero copy. Even where information about the medicine is discoverable on a deeper page, it cannot sit on the front door.
- Conditions, not products. "Treatment of fine lines and wrinkles" is workable language. "Botox", "anti-wrinkle injection", "wrinkle relaxant injection" or any indirect reference to the active substance is not.
- Factual information after consultation. A logged-in patient page or post-consultation document can carry factual information mirroring the patient information leaflet. It cannot be promotional, and it cannot be discoverable from the public homepage.
The point of the structure is that the patient is making a decision in the context of a clinical consultation, not in response to an ad. That is the test the regulator applies.
What clinics still get wrong on social media
Instagram and TikTok carry the densest concentration of breaches. The ASA's published rulings and practical advice repeatedly address the same patterns: brand-name hashtags, seasonal promotions such as "Back to School Botox" (cited in a 2023 ruling for exploiting insecurities about ageing), celebrity endorsements, before-and-after photographs treated as efficacy claims, comparative phrasing such as "Better than Botox", misleading product names such as "Beautox" that imply the POM, and price-led promotions that name or implicitly identify the medicine. Each of these breaches Regulation 284 or CAP rule 12.12.
The defensible position for a clinic on social is to work the consultation conversation, not the medicine. Educational content about facial ageing, the consultation process, the practitioner's qualifications, the standards the clinic operates under (such as JCCP register status or CQC registration), and the conditions a consultation can address all sit on the right side of the rule. The medicine itself stays out of the post.
Where the licensing scheme intersects this
The UK aesthetics licensing scheme under the Health and Care Act 2022 is a separate framework, but it intersects POM advertising at one point: licensed premises and licensed practitioners will be expected to operate to the standards already set out by the MHRA, the JCCP and the ASA. A clinic that has built its consumer marketing around the medicine itself will need to rework that marketing before it sits comfortably under the licensing regime.
If you want the structured walk-through, the RAG Pathway is the four-week programme designed to land practitioners aligned with the eight regulators we teach against, including MHRA, JCCP and ASA, before the licensing scheme tightens. It includes a marketing-compliance audit module that puts the website, the social grid and the price list against Regulation 284 and the CAP Code line by line.
FAQ
Can I name "Botox" on my clinic's About page?
No. Botox is a brand name for a POM. Regulation 284 prohibits advertisements likely to lead to public use, and the ASA's rulings treat any public-facing reference, including the About page, as captured. The same applies to "botulinum toxin", "anti-wrinkle injection" and other indirect references.
Can I list a price for botulinum toxin treatments?
Not on a public-facing page. Price information is treated as advertising. Pricing for POMs sits behind the consultation, not in the ad. The ASA position on this has been consistent since the original Botox enforcement notice.
Are before-and-after photos allowed?
Not where they show the effect of a POM. Before-and-after photographs of botulinum toxin treatments are treated as efficacy claims for the medicine, which is exactly what the rule prohibits. Before-and-after content for non-POM treatments (skin boosters that are not POMs, microneedling, peels) is treated separately.
What about hashtags like #botox or #brotox?
The ASA's published practical advice names brand-name hashtags as caught by the rule. The hashtag is part of the publication, and it leads consumers towards the POM. The rule applies to the substance of the communication, not just the headline copy.
Does this apply to clinic newsletters?
Yes. The Blue Guide and CAP Code apply across media. A clinic newsletter, whether email, paper or in-app, sent to a public mailing list, sits inside the consumer-advertising frame and inside Regulation 284. Communications to a patient already under consultation are treated differently, but the boundary needs to be defensible.
Who enforces this if a clinic is found in breach?
Two routes. The ASA upholds rulings against the advertiser, requires the ad to be removed, and lists the case publicly. The MHRA can take regulatory action under the Human Medicines Regulations, and the GOV.UK enforcement publications list cases where it has done so. Reputational damage from an upheld ruling typically outruns the financial penalty.